The California Life Sciences Institute Hosts First CLSI Women Life Science Executives Dinner
Entrepreneurship
Big3Bio interviews Inflammatix (FAST Fall 2017): Interrogating the Immune System for Diagnosing Infection | Read More
SciBac(FAST Fall 2016) selected to present and compete at Partnering for Growth’s Biotech Innovation Showcase on March 20 | More Info
Cairn Biosciences(FAST Fall 2015) featured in the San Francisco Business Times on the importance of Mission Bay’s incubators and the value they bring to entrepreneurs for getting access to world-class facilities | Read More
GigaGen (FAST Spring 2015) presented methods for rapid immune-oncology antibody discovery at 2018 Keystone Symposia on Antibodies as Drugs | Read More
Sandstone Diagnostics (FAST Fall 2013) showcased Trak™ Fertility Products at HIMSS 2018 Intelligent Health Pavilion™ | Read More
The FAST Advisory Program provides select entrepreneurs with intensive team review and coaching to perfect their business model, product development plans, and to build a compelling commercialization strategy. Experienced entrepreneurs, product and business experts (which may include clinical development, regulatory, reimbursement and business development specialists) will advise selected Fellows during a twelve-week program, culminating in a Final FAST Showcase to a broad audience that includes potential investors and partners.
CARB-Xannounced its 2018 rounds of funding to support research into the development of antibiotics, vaccines, diagnostics, devices, and other life-saving products to respond to the threat of drug-resistant bacteria | Read More
Powered by CARB-X company, Debiopharm Group announced an investment in antibiotic development with acquisition of ABAC Therapeutics | Read More
CARB-X awards up to $4.0 million to Curza to develop a new class of antibiotics to treat a broad spectrum of life-threatening Gram-negative bacteria that are resistant to existing antibiotics | Read More
CARB-X awards up to $6.8 million to Macrolide Pharmaceuticals to develop novel macrolide antibiotics with gram negative activity to treat drug-resistant complicated urinary tract infections | Read More
CARB-X awards up to $5.2 million to Bay Area’s MicuRx Pharmaceuticals for the early development of a polymyxin antibiotic MRX-8 to treat multi-drug resistant Gram-negative superbugs | Read More
CARB-X awards up to $2.0 million to T2 Biosystems for the development of new magnetic resonance tests to quickly diagnose drug-resistant infections in whole blood | Read More
Wellcome Trustreleased an RFP to develop a business plan for a sustainable clinical trial network for antibiotic development | More Info
Novo Holdings announced the launch of the $165 million REPAIR Impact Fund, commissioned by Novo Nordisk Foundation, to invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance. First call for applications begins April 1 and is open to companies in Europe and Israel. Call for applications from US-based companies is expected this fall. | Read More
For more information on CARB-X, please contact Heather Shane, hshane@califesciences.org or Amy Xu, axu@califesciences.orgScientists at the University of Leeds are re-examining previously discarded chemical compounds by applying advances in science and technology to test more precisely to see if they could be developed for new antibiotics | Read More
CARB-X is one of the world's largest public-private partnership devoted to early stage antibacterial R&D. Funded by ASPR/BARDA and Wellcome Trust, with in-kind support from NIAID, CARB-X is investing up to $455 million from 2016-2021 to support innovative products from ‘hit-to-lead’ phase through to Phase 1 clinical trials. CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X operates through Boston University. Other partners include RTI International, the Broad Institute of Harvard and MIT, MassBio, and the California Life Sciences Institute (CLSI). http://www.carb-x.org/.
4/6 Deadline to submit product profiles to participate in Exploring the Antibiotic Pipeline Symposium at IDWeek 2018 (in San Francisco this October). Preference for compounds that are in clinical development, focusing on novel mechanisms and approaches, but not yet approved by FDA. For more details, contact jomohr90@gmail.com
4/21
28th European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain
CLSI helps build the next generation of life science professionals by bringing industry and institutions of learning together to improve STEM education in California and to inspire and develop life science careers. CLSI also works to ensure that the current and anticipated talent needs of the industry are met, and that the workforce pipeline for the industry remains strong.
Upcoming Events
3/13
SFSU MBA Information Session Webinar for Biotech Professionals
California Life Sciences Institute (CLSI) supports the foundations of innovation that have made California home to the world’s most prominent life sciences ecosystem. Our mission is to maintain California’s leadership in life sciences innovation through support of entrepreneurship, education and career development. CLSI also serves as an accelerator for CARB-X, the world’s largest public-private partnership devoted to early stage antibacterial R&D.
CLSI is an affiliate of the California Life Sciences Association (CLSA), which represents California’s leading life sciences organizations. The California Life Sciences Institute is a non-profit 501(c)(3), and was established in 1990 as the BayBio Institute.
California Life Sciences Institute 701 Gateway Boulevard Suite 440 South San Francisco CA 94080 USA
You received this email because you are subscribed to Marketing Information from California Life Sciences Association .
Update your email preferences to choose the types of emails you receive.